Insmed (INSM)
(Delayed Data from NSDQ)
$25.81 USD
+0.54 (2.14%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $25.81 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth A Momentum F VGM
Price, Consensus and EPS Surprise
INSM 25.81 +0.54(2.14%)
Will INSM be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for INSM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for INSM
Insmed (INSM) Reports Q4 Loss, Misses Revenue Estimates
Insmed (INSM) Expected to Beat Earnings Estimates: Should You Buy?
INSM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Insmed (INSM) Reports Q3 Loss, Tops Revenue Estimates
Amgen (AMGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Will Insmed (INSM) Report Negative Earnings Next Week? What You Should Know
Other News for INSM
Spero Therapeutics Delivers On Game Plan To Create Shareholder Value
Roblox upgraded, Qualcomm initiated: Wall Street's top analyst calls
Roblox upgraded, Qualcomm initiated: Wall Street's top analyst calls
Analysts Conflicted on These Healthcare Names: Cartesian Therapeutics (RNAC), Insmed (INSM) and BioNTech SE (BNTX)
Insmed initiated with bullish view at Truist, here's why